Logo image of INAB

IN8BIO INC (INAB) Stock Fundamental Analysis

NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD

2.13  -0.02 (-0.93%)

After market: 2.11 -0.02 (-0.94%)

Fundamental Rating

1

Taking everything into account, INAB scores 1 out of 10 in our fundamental rating. INAB was compared to 553 industry peers in the Biotechnology industry. INAB may be in some trouble as it scores bad on both profitability and health. INAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INAB had negative earnings in the past year.
In the past year INAB has reported a negative cash flow from operations.
In the past 5 years INAB always reported negative net income.
In the past 5 years INAB always reported negative operating cash flow.
INAB Yearly Net Income VS EBIT VS OCF VS FCFINAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

INAB has a worse Return On Assets (-138.03%) than 83.91% of its industry peers.
With a Return On Equity value of -197.63%, INAB is not doing good in the industry: 67.27% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -138.03%
ROE -197.63%
ROIC N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
INAB Yearly ROA, ROE, ROICINAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INAB Yearly Profit, Operating, Gross MarginsINAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

INAB has more shares outstanding than it did 1 year ago.
INAB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for INAB is higher compared to a year ago.
INAB Yearly Shares OutstandingINAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
INAB Yearly Total Debt VS Total AssetsINAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -12.18, we must say that INAB is in the distress zone and has some risk of bankruptcy.
INAB has a worse Altman-Z score (-12.18) than 77.03% of its industry peers.
INAB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
INAB has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: INAB outperforms 41.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -12.18
ROIC/WACCN/A
WACCN/A
INAB Yearly LT Debt VS Equity VS FCFINAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 4.30 indicates that INAB has no problem at all paying its short term obligations.
INAB has a Current ratio (4.30) which is in line with its industry peers.
INAB has a Quick Ratio of 4.30. This indicates that INAB is financially healthy and has no problem in meeting its short term obligations.
INAB has a Quick ratio of 4.30. This is comparable to the rest of the industry: INAB outperforms 49.73% of its industry peers.
Industry RankSector Rank
Current Ratio 4.3
Quick Ratio 4.3
INAB Yearly Current Assets VS Current LiabilitesINAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.55% over the past year.
EPS 1Y (TTM)50.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.09% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.72%
EPS Next 2Y27.47%
EPS Next 3Y18.41%
EPS Next 5Y19.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INAB Yearly Revenue VS EstimatesINAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 50M 100M 150M
INAB Yearly EPS VS EstimatesINAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INAB Price Earnings VS Forward Price EarningsINAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INAB Per share dataINAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as INAB's earnings are expected to grow with 18.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.47%
EPS Next 3Y18.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IN8BIO INC

NASDAQ:INAB (7/31/2025, 8:00:02 PM)

After market: 2.11 -0.02 (-0.94%)

2.13

-0.02 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-01 2025-08-01/amc
Inst Owners19.89%
Inst Owner Change-0.99%
Ins Owners4.3%
Ins Owner Change0%
Market Cap7.33M
Analysts82
Price Target127.76 (5898.12%)
Short Float %4.4%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.39%
Min EPS beat(2)-2.94%
Max EPS beat(2)47.71%
EPS beat(4)2
Avg EPS beat(4)10.5%
Min EPS beat(4)-10.88%
Max EPS beat(4)47.71%
EPS beat(8)4
Avg EPS beat(8)0.9%
EPS beat(12)5
Avg EPS beat(12)-3.45%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.3%
PT rev (3m)4694.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)-6.35%
EPS NY rev (3m)-3090.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-13.5
EYN/A
EPS(NY)-6.53
Fwd EYN/A
FCF(TTM)-5.66
FCFYN/A
OCF(TTM)-5.63
OCFYN/A
SpS0
BVpS4.03
TBVpS4.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -138.03%
ROE -197.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.3
Quick Ratio 4.3
Altman-Z -12.18
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)217.04%
Cap/Depr(5y)140.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65%
EPS Next Y60.72%
EPS Next 2Y27.47%
EPS Next 3Y18.41%
EPS Next 5Y19.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.28%
EBIT Next 3Y-17.46%
EBIT Next 5Y-5.55%
FCF growth 1Y36.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.33%
OCF growth 3YN/A
OCF growth 5YN/A